Reflect ScientificRSCF EBITDA Margin % is 12.75% as of Sep. 2025. The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Reflect Scientific ranks worse than 54.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Reflect Scientific's EBITDA for the
three
months ended in Sep. 2025 was $0.05 Mil. Reflect Scientific's Revenue for the
three
months ended in Sep. 2025 was $0.40 Mil. Therefore, Reflect Scientific's EBITDA margin for the quarter that ended in Sep. 2025 was 12.75%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Reflect Scientific EBITDA Margin % Related Terms
Reflect Scientific EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Reflect Scientific's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RSCF vs GCTK, CBSC, NXGL: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Reflect Scientific's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Reflect Scientific EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Reflect Scientific's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Reflect Scientific's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reflect Scientific (RSCF) has a EBITDA Margin % of 12.75% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Reflect Scientific and its competitors. According to the industry distribution chart, Reflect Scientific ranks #442 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 54.2%.
Is Reflect Scientific's EBITDA Margin % too high?
Reflect Scientific's current EBITDA Margin % is 12.75%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Reflect Scientific's value of 12.75% is 70.6% above this industry median. Based on the distribution chart, Reflect Scientific ranks #442 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Reflect Scientific's EBITDA Margin % compare to GCTK and CBSC?
According to the Medical Devices & Instruments industry distribution chart, Reflect Scientific ranks #442 out of 816 companies for EBITDA Margin %. This places Reflect Scientific in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Reflect Scientific's value of 12.75% is 70.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Reflect Scientific's current EBITDA Margin % of 12.75% is 70.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Reflect Scientific and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Reflect Scientific's current EBITDA Margin % is 12.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reflect Scientific stock overvalued right now?
Reflect Scientific (RSCF) has a current EBITDA Margin % of 12.75%. The current EBITDA Margin % is 12.75% and 70.6% above the Medical Devices & Instruments industry median of 7.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Reflect Scientific (RSCF), the current EBITDA Margin % is 12.75% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Reflect Scientific Inc is engaged in the manufacture and distribution of products targeted at the life science market. The group's customers include hospitals, diagnostic laboratories, pharmaceutical and biotech companies, cold chain management, universities, government and private sector research facilities, and chemical and industrial companies. Its growing product portfolio includes ultra-low temperature freezers, blast freezers, solvent chillers, and refrigerated transportation in addition to supplying OEM products to the life sciences industry. The group's products are Cryometrix, GCFerrules, and Visacon. It recognizes revenue from the sale of scientific equipment for the life sciences and manufacturing industries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSCF has been successfully added to your 